SHENZHEN, China, Aug. 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - is pleased to announce today that Mellow Hope, an operating subsidiary of HTDS, is providing another government tender. This one is for 50,000 doses of Mevac A in Sri Lanka. Mellow Hope maintains a good relationship with a local partner, who is one of the leading pharmaceutical companies in Sir Lanka.
Mr. Terry Yuan, CEO of HTDS, said "Although these are tenders they are worthwhile mentioning especially when our confidence is high that we will be awarded this tender. We are hoping to be in a position to release the results October 2009 for Sri Lanka. Just as we announced our Chile tender (see news Aug 07, 2009), we are pleased to announce that significant strides were made on that front as well. Because this is a significant deal (the largest single order the company will fulfill to date), these strides required my attendance in Chile this week to iron out any fine details which may remain outstanding. Regrettably due to the sudden required trip to Chile, I was unable due to scheduling to attend the Expo in Toronto Canada where HTDS' interests in Slavica Bio Chem and Mellow Hope were proudly exhibited by our Science correspondent for our shareholders, and other professionals that attended the event. Now, subsequent to the Expo we have received many inquiries where amongst other things, shareholders were concerned about certain "reports" that were being posted or circulating on the Internet that some individuals have "met with CEO of HTDS" and the prognoses for HTDS is not good, and other similar falsehoods. Again, I was unable due to scheduling to attend the Expo in Toronto, and no such conversation took place, nor is there any truth to it. I know that our investor relations company (Mina Mar Group) takes these matters quite seriously and takes legal action against these types of activities. We also ask our followers to review our "Get the Facts Right" corporate policy, and to rely only upon official company releases, and filings on Pink Sheets, and not those with hidden motives.
"We have recently re filed our Adequate Disclosure with pink sheets which is as current as it possibly can be. We have also heard back from Pink Sheets regarding our aspirations of obtaining the 'current issuer ranking'. Additional supporting documents and other clarifications will be filed this week to obtain this ranking however the substance and the content of our Adequate Disclosure remains the same, and we again remind our followers that only this document filed with pink Sheets and our official web sites are the most current and accurate sources of information."
The company intends to provide further updates on a timely basis.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings (www.pinksheets.com), and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation describing the risks of investing in penny stocks.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved